Literature DB >> 9844934

Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects.

W A Hudson1, Q Li, C Le, J H Kersey.   

Abstract

While it is known that mice with genetic immune defects are useful for establishing durable engraftment of human tumor xenografts, the relative role of components of host innate and adoptive immunity in engraftment has not been determined. We directly compared the ability of four strains of genetically immunodeficient mice (NOD/SCID, SCID, Nude and Rag-1-deficient) to successfully engraft and support the human cell lines Daudi, Raji, Namalwa and Molt-4 as subcutaneous tumors. We additionally examined the effect of further immunosuppression of the mice by whole body irradiation at a dose of 600 cGy for Nude and Rag-1 and 300 cGy for SCID mice and by administration of anti-natural killer (asialo-GM1) antibody on tumor growth. Mice with each of the defects supported xenografts to varying degrees. We found differences in growth characteristics in the cell lines tested, with Namalwa consistently producing the largest tumors. With all cell lines studied, optimal growth was achieved using NOD/SCID mice. Overall, tumor growth was somewhat enhanced by pretreatment with radiation with little additional benefit from the addition of anti-asialo-GM1 antibody. The importance of multiple components of the innate and adoptive immune system in xenotransplantation were best demonstrated when results in untreated NOD/SCID mice were compared to SCID, nude and RAG-1-deficient mice. The NOD/SCID mouse with or without additional immunosuppression provides the optimal model for the study of the biology and treatment of human leukemias and lymphomas.

Entities:  

Mesh:

Year:  1998        PMID: 9844934     DOI: 10.1038/sj.leu.2401236

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

1.  Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

Authors:  Stefano Indraccolo; Laura Stievano; Sonia Minuzzo; Valeria Tosello; Giovanni Esposito; Erich Piovan; Rita Zamarchi; Luigi Chieco-Bianchi; Alberto Amadori
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

Review 2.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

3.  Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.

Authors:  Yasuyuki Miyake; Yasushi Okoshi; Takayuki Machino; Shigeru Chiba
Journal:  Int J Hematol       Date:  2010-09-07       Impact factor: 2.490

4.  Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.

Authors:  Beatriz M Carreno; Joel R Garbow; Grant R Kolar; Erin N Jackson; John A Engelbach; Michelle Becker-Hapak; Leonidas N Carayannopoulos; David Piwnica-Worms; Gerald P Linette
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

5.  Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Authors:  Gadi Gazit Bornstein; Christophe Quéva; Mohammad Tabrizi; Anne van Abbema; Carlos Chavez; Ping Wang; Orit Foord; Kiran Ahluwalia; Naomi Laing; Sandhya Raja; Shenghua Wen; Larry L Green; Xiaodong Yang; Carl Webster; Ross Stewart; David Blakey
Journal:  Invest New Drugs       Date:  2009-07-21       Impact factor: 3.850

6.  E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia.

Authors:  Rebecca J Greenwald; Joseph R Tumang; Anupama Sinha; Nicolas Currier; Robert D Cardiff; Thomas L Rothstein; Douglas V Faller; Gerald V Denis
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

Review 7.  Immunodeficient mouse models of lymphoid tumors.

Authors:  Kazunori Imada
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

8.  Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.

Authors:  S M Büchner; K Sliva; H Bonig; I Völker; Z Waibler; J Kirberg; B S Schnierle
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

9.  Endoscopy-guided orthotopic implantation of colorectal cancer cells results in metastatic colorectal cancer in mice.

Authors:  Dominik Bettenworth; Marcus M Mücke; Katrin Schwegmann; Andreas Faust; Christopher Poremba; Michael Schäfers; Dirk Domagk; Philipp Lenz
Journal:  Clin Exp Metastasis       Date:  2016-05-04       Impact factor: 5.150

10.  Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.

Authors:  Assia L Angelova; Marc Aprahamian; Ginette Balboni; Henri-Jacques Delecluse; Regina Feederle; Irina Kiprianova; Svitlana P Grekova; Angel S Galabov; Mathias Witzens-Harig; Anthony D Ho; Jean Rommelaere; Zahari Raykov
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.